Onconetix Implements 1-for-10 Reverse Stock Split For Nasdaq Compliance; Stock Down

Onconetix approved a 1-for-10 reverse stock split of its outstanding common shares, effective May 21, 2026. The move is typically aimed at maintaining listing compliance and improving share-price optics rather than changing intrinsic value. The announcement is routine and likely to have only a limited near-term market impact.

Analysis

Onconetix approved a 1-for-10 reverse stock split of its outstanding common shares, effective May 21, 2026. The move is typically aimed at maintaining listing compliance and improving share-price optics rather than changing intrinsic value. The announcement is routine and likely to have only a limited near-term market impact.